When South Korea’s Samsung Biologics announced plans Thursday to split its CDMO and biosimilar businesses into separate entities, the news drew praise not just for strategic clarity but for the way it was executed. In a market where retail investors have grown wary of corporate spin-offs, this one felt refreshingly different- and fair.

Set for completion in October 2025, the split will leave the original Samsung Biologics focused solely on its core contract development and manufacturing (CDMO) operations while a newly created Samsung Epis Holdings will take over the biosimilar business. That new entity will fully absorb Samsung Bioepis, which is currently a subsidiary of Samsung Biologics. More than a mere technical reshuffle, the split addresses a long-standing issue: conflict of interest. Some global pharmaceutical clients have reportedly hesitated to outsource production to Samsung Biologics out of fear that manufacturing expertise might be leaked to Bioepis, its in-house biosimilar arm. Decoupling the two allows each to sharpen its competitive edge while giving Samsung Epis Holdings a cleaner path toward a potential IPO to fund new drug development.

But what truly sets this split apart is the way it was conducted. In an era when large Korean conglomerates increasingly opt for physical splits - creating subsidiaries that leave minority shareholders sidelined - Samsung Biologics chose an equity-based spin-off. That means retail investors receive shares in the new entity in proportion to their holdings. No dilution, no exclusion. It is a refreshing show of governance in a market still scarred by spin-offs that have left small investors behind while funneling value into the hands of parent companies.

Of course, a just process does not guarantee future performance. The real test lies ahead, in the companies’ ability to deliver operational gains, scientific breakthroughs, and job creation.

[ⓒ 매일경제 & mk.co.kr, 무단 전재, 재배포 및 AI학습 이용 금지]